GRP78 molecular chaperone revealed as drug target for COVID-19
Using computer modelling, a team has shown that a molecular chaperone called GRP78 could be targeted by drugs in strategies to treat COVID-19.
List view / Grid view
Using computer modelling, a team has shown that a molecular chaperone called GRP78 could be targeted by drugs in strategies to treat COVID-19.
Researchers have used fragment screening alongside computational docking to reveal 20 hit antiviral compounds against SARS-CoV-2.
Researchers are working to build a complete, all-atom model of the exterior of the coronavirus to aid in drug design.
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
A new method has been developed by researchers to create synthetic molecules which replicate natural structures and have potential medicinal uses.
The carbon hydrogen functionalisation process could be used to make 3D scaffolds for pharmaceutical compounds, say researchers.
Dr Goodwin is the latest top-level scientist to join DTR's advisory board
G protein-coupled receptors are the key target of a large number of drugs, scientists have now been able to show more precisely how these receptors act in the cell interior...
Investments are now being made to roll out this innovation across healthcare and broaden the scope of the research in this field.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing 15 new Research Training Groups to further support early research...
Researchers find key molecule that could lead to new therapies for anaemia and other iron disorders.
Scientists have pinpointed a chemical signal that worsens inflammation linked to a life-threatening lung condition. The discovery could eventually lead to new therapies for this disease, which can be fatal for up to half of those affected.
Researchers from UPM and CSIC have employed waste from the agri-food industry to develop biomaterials that are able to act as matrices to regenerate bone and cartilage tissues, which is of great interest for the treatment of diseases related to ageing.
Two-dimensional monolayer cell proliferation assays for cancer drug discovery have enabled large-scale screens. But they represent a simplified view of oncogenes or tumour suppressor genes as the genetic drivers of cancer cell proliferation.
19 July 2016 | By Niamh Louise Marriott
A*STAR and MSD have formed a two year collaboration aimed at improving cellular delivery of macrocyclic peptides...